المشاركة الأصلية كتبت بواسطة مغربي عابر انا يا صديقي لا اعلق فقط بنائا على تجربتي فقط...ولاكن على تجارب الكل و على احدث التحليلات الحديثة للادوية Anxiety, agitation, insomnia Fluoxetine has been associated with highest rate of anxiety and agitation1. Escitalopram and paroxetine are less likely to cause insomnia than fluoxetine and sertraline. Escitalopram and citalopram have been associated with low rates of insomnia, anxiety, and other activating side effects هدا جزئ من مقال علمي نسخت لك الجزئ البسيط منه فقط... الدي ممكن ان تستوعبه . بروزاك و سيرترالين لا تعطى لمرضى اهلع و القلق العام هي منشطة ليست مهدئة .FDA لم تعترف بادوية كان لها تاتير ايجابي جدا جدا في جميع المجالات فقط لانها ليست من صنع شركات امريكية و الائحة موجودة ادا اردتها.هدا يعني ان مصدتقيةfda مشكوك فيها. و حتى ان اعتمدنا على fda سيرترالين فقط يعطى للقلق offlabel و تقريبا جميع revwies كانت سلبية يعني انه يزيد من القلق. على اي يا رفيق انت لست مجبر بالتعليق على تدخلاتي بدالك الشكل العنيف انا هنا لاشراك تجاربي و تجارب جميع مرضى العالم مع اعضاء المنتدى في سبيل الله فقط...فادا كنت تملك un savoir شاركه معنا و نكون ممتنين عوض تعاليق فارغة

Initial U.S. Approval: 1991

ZOLOFT is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of :

Major depressive disorder (MDD)
Obsessive-compulsive disorder (OCD)
Panic disorder (PD)
Post-traumatic stress disorder (PTSD)
Social anxiety disorder (SAD)
Premenstrual dysphoric disorder (PMDD)

14.3 Panic Disorder
The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double-blind, placebo-controlled studies (Studies PD-1, PD-2, and PD-3) of adult outpatients who had a primary diagnosis of PD (DSM-III-R), with or without agoraphobia.

Studies PD-1 and PD-2 were 10-week flexible dose studies of ZOLOFT (N=80 study PD-1 and N=88 study PD-2) compared to placebo (N=176 study PD-1 and PD-2). In both studies, ZOLOFT was initiated at 25 mg/day for the first week, then titrated in weekly increments of 50 mg per day to a maximum dose of 200 mg/day on the basis of clinical response and toleration.
The mean ZOLOFT doses for completers to 10 weeks were 131 mg/day and 144 mg/day, respectively, for Studies PD-1 and PD-2. In these studies, ZOLOFT was shown to be statistically significantly more effective than placebo on change from baseline in panic attack frequency and on the Clinical Global Impression Severity (CGI-S) of Illness and Global Improvement (CGI-I) scores. The difference between ZOLOFT and placebo in reduction from baseline in the number of full
panic attacks was approximatly 2 panic attacks per week in both studies.
Study PD-3 was a 12-week randomized, double-blind fixed-dose study, including ZOLOFT doses of 50, 100, and 200 mg/day. Patients receiving ZOLOFT (50 mg N=43, 100 mg N=44, 200 mg N=45) experienced a statistically significantly greater reduction in panic attack frequency than patients receiving placebo (N=45).
Study PD-3 was not readily interpretable regarding a dose response relationship for effectiveness.

Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age, race, or gender.
In Study PD-4, patients meeting DSM-III-R criteria for PD who had responded during a 52-week open trial on ZOLOFT 50-200 mg/day (n=183) were randomized to continuation of ZOLOFT or to substitution of placebo for up to 28 weeks of observation for discontinuation due to relapse or insufficient clinical response. Response during the open phase was defined as a CGI-I score of 1(very much improved) or 2 (much improved). Insufficient clinical response in the double-blind phase indicated a worsening of the patient’s condition that resulted in study discontinuation, as assessed by the investigator. Relapse during the double-blind phase was defined as the following conditions being met on three consecutive visits:
(1) CGI-I ≥ 3;
(2) meets DSM-III-R criteria for PD;
(3) number of panic attacks greater than at baseline.

Patients receiving continued ZOLOFT treatment experienced a statistically significantly lower rate of discontinuation due to relapse or insufficient clinical response over the subsequent 28 weeks compared to those receiving placebo. This pattern was demonstrated in male and female subjects.